<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433522</url>
  </required_header>
  <id_info>
    <org_study_id>P110146 extended</org_study_id>
    <secondary_id>2012-001963-66</secondary_id>
    <nct_id>NCT02433522</nct_id>
  </id_info>
  <brief_title>Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab</brief_title>
  <acronym>MAINRITSAN3</acronym>
  <official_title>Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MAINRITSAN study compared Rituximab and azathioprine as maintenance therapy for&#xD;
      ANCA-associated vasculitides. In this study, Rituximab (5 infusions at D1, D15, M6, M12, M18)&#xD;
      was superior to azathioprine (2 mg/kg/day) to prevent relapses of AAV 28 months after the&#xD;
      inclusion (Guillevin et al. NEJM 2014). Nevertheless, in the follow-up study of MAINRITSAN,&#xD;
      up to 30% of patients experienced a relapse 38 months after the last rituximab infusion&#xD;
      (unpublished data). Right now, no randomized controlled study has been carried in order to&#xD;
      evaluate the best duration of the maintenance treatment with rituximab.&#xD;
&#xD;
      The investigators objective is to evaluate the efficacy of a long term rituximab treatment to&#xD;
      prevent relapses of ANCA-associated vasculitis in patients in remission after a first phase&#xD;
      of rituximab maintenance treatment.&#xD;
&#xD;
      The investigators will conduct a randomized placebo-controlled trial of a long term rituximab&#xD;
      maintenance treatment (46 months) against a conventional maintenance treatment (18 months).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2015</start_date>
  <completion_date type="Actual">August 16, 2018</completion_date>
  <primary_completion_date type="Actual">August 16, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasculitis score 2003 (BVAS 2003 )</measure>
    <time_frame>28 months</time_frame>
    <description>Relapse free survival rates (BVAS &gt; 0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events,</measure>
    <time_frame>28 months</time_frame>
    <description>adverse events including infectious effects and their severity in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients experiencing at least one adverse event in both arms</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation of ANCA level with the clinical events</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANCA level during follow-up</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation B-Lymphocytes CD-19 level with the clinical events</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-Lymphocytes CD-19 level during follow-up</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of B memory cells during follow-up in both arms</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation number of B memory cells with the clinical events</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with ANCA in each arm</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time frame to death in both arms</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time frame of first minor relapse</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time frame of first major relapse</measure>
    <time_frame>28 months</time_frame>
    <description>&quot;the reappearance of disease activity or worsening, with a Birmingham Vasculitis Activity Score &gt;0, and involvement of one or more major organs, disease-related life-threatening events, or both&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated dose of corticosteroid treatment</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of damages</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of of gammaglobulins</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life : SF36 (The Short Form (36) Health Survey)</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional capacities : HAQ (Health Assessment Questionnaire )</measure>
    <time_frame>28 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>ANCA-associated Vasculitides</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg rituximab infusion at the randomization visit and every 6 months for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo infusion at the randomization visit and every 6 months for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        First, patients must have been included in MAINRITSAN 2 and in addition to meeting the&#xD;
        criteria for inclusion and non-inclusion.&#xD;
&#xD;
        MAINRITSAN 2 inclusion criteria:&#xD;
&#xD;
          -  Granulomatosis with Polyangiitis Or microscopic polyangiitis complying Or&#xD;
             kidney-limited disease With or without detectable ANCA (anti-neutrophil cytoplasmic&#xD;
             antibodies) at the time of diagnosis or relapse, and at remission.&#xD;
&#xD;
          -  Who have achieved remission using a treatment combining corticosteroids and an&#xD;
             immunosuppressive agent, including corticosteroids, cyclophosphamide IV or oral (the&#xD;
             use of another immunosuppressant is allowed, according to the current French&#xD;
             guidelines, as well as plasma exchanges and/or IV immunoglobulins, or rituximab).&#xD;
&#xD;
          -  Interval of 1 month between the end of the immunosuppressant treatment and the&#xD;
             randomization time if cyclophosphamide or methotrexate were used, interval between 4&#xD;
             and 6 months if rituximab was used&#xD;
&#xD;
          -  Age &gt; 18 years without age limit higher when the diagnosis is confirmed.&#xD;
&#xD;
          -  Informed and having signed the consent form to take part in the study.&#xD;
&#xD;
        and Patients must meet all of the following criteria:&#xD;
&#xD;
          -  In complete remission (BVAS 0) at 28 months of MAINRITSAN2 study.&#xD;
&#xD;
          -  Informed patient who accepted to participate in MAINRITSAN 2 and who signed the&#xD;
             informed consent to this extension.&#xD;
&#xD;
          -  Randomized on the day of the evaluation of the primary endpoint of MAINRITSAN 2 during&#xD;
             the visit M28 (last visit of the protocol).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eosinophilic granulomatosis with polyangiitis (EGPA)&#xD;
&#xD;
          -  History of severe allergic manifestations or anaphylactic manifestations following&#xD;
             humanized or murine monoclonal antibodies infusions&#xD;
&#xD;
          -  Pregnant or breast feeding women. Contraception is required for women who could be&#xD;
             pregnant during treatment follow up and during the year following the last infusion.&#xD;
&#xD;
          -  Infection by HIV (positive serology), HCV (positive serology), or HBV (HBsAg positive&#xD;
             or anti-HBc antibody positive with anti-HBs antibody negative)&#xD;
&#xD;
          -  Uncontrolled infection at time of inclusion in the extended follow-up study.&#xD;
&#xD;
          -  Other severe bacterial, viral , mycobacterial or fungal infection(s), occurring within&#xD;
             the last 3 months before of randomization. A severe infection is defined by the&#xD;
             hospitalization, a life or organ threatening.&#xD;
&#xD;
          -  Severe chronic obstructive bronchopathy (FEV &lt; 50% or dyspnea stage III).&#xD;
&#xD;
          -  Cardiac failure, stage IV according to the NYHA classification.&#xD;
&#xD;
          -  Recent history of coronary artery disease (&lt;1 month).&#xD;
&#xD;
          -  Ongoing malignancy or hematologic disease within 5 years before inclusion.&#xD;
&#xD;
          -  Patient with severe immunodepression characterized by clinical manifestations.&#xD;
&#xD;
          -  Participation to another concomitant therapeutic study (except observational studies&#xD;
             or studies without therapeutic intervention).&#xD;
&#xD;
          -  Psychiatric disease that may interfere with the study.&#xD;
&#xD;
          -  Non affiliation to a health insurance.&#xD;
&#xD;
          -  Uncontrolled severe cardiac disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loic GUILLEVIN, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Pagnoux C, Guillevin L; French Vasculitis Study Group; MAINRITSAN investigators. Rituximab or azathioprine maintenance in ANCA-associated vasculitis. N Engl J Med. 2015 Jan 22;372(4):386-7. doi: 10.1056/NEJMc1414728.</citation>
    <PMID>25607433</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANCA-associated vasculitides</keyword>
  <keyword>Maintenance treatment</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Granulomatosis with polyangiitis</keyword>
  <keyword>Microscopic polyangiitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

